stockrowGRAIL, Inc.
GRAL Healthcare Diagnostics & Research
GRAIL, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $147.2 million, up 17.2% from fiscal 2024.
- Revenue
- +3.71%
- EPS
- +10.2%
- Free cash flow
- −24.9%
Quarter to September 2026, against a year earlier
Follow GRAL
Alert me
GRAIL, Inc. (GRAL) Return on assets
GRAIL, Inc.'s return on assets over the twelve months to 30 September 2026 was −15.2%, down 1.4 percentage points from fiscal 2025 (−13.8%). That is below the Diagnostics & Research industry median of −6.05% and above the Healthcare sector median of −29.3%.
Return on assets, annual
Embed this chart
Annual newest first
| Period | Return on assets | Change (points) |
|---|---|---|
| FY2025 | −13.8% | 44.95 |
| FY2024 | −58.8% | 16.12 |
| FY2023 | −74.9% | (74.90) |
| FY2022 | 0.00% | — |
Return on assets against peers
| Company | Return on assets |
|---|---|
| CDNA CareDx, Inc. compare | 24.0% |
| BLLN BillionToOne, Inc. compare | 9.02% |
| VCYT Veracyte, Inc. compare | 8.63% |
| QGEN QIAGEN N.V. compare | 6.99% |
| SHC Sotera Health Company compare | 5.28% |
| ICLR ICON PLC compare | 2.74% |
| RDNT RadNet, Inc. compare | −0.55% |
| ADPT Adaptive Biotechnologies Corporation compare | −12.0% |
| GRAL GRAIL, Inc. | −15.2% |
| Diagnostics & Research industry median | −6.05% |
| Healthcare sector median | −29.3% |
| Market median | 0.00% |
What Return on assets is
ROA tells an investor how much profit a company earns for shareholders from the assets it uses to run its business.
Annual: Net Income Allotted to Shareholders ÷ Average Assets; TTM: Net Income Allotted to Shareholders ÷ Average Assets (latest quarter)
More on GRAL
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement